Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
Inconsistent response in freezing of gait (FOG) with levodopa treatment or STN DBS makes the pathogenesis difficult to understand. We studied brain areas associated with the expression of STN DBS effect on parkinsonian motor deficits and FOG. Ten Parkinson's disease patients with typical FOG were included. One month before STN DBS, we performed [(18)F]-deoxyglucose PET scans and measured the UPDRS motor and modified FOG (mFOG) scores during levodopa off and on periods. At two months after STN DBS, same rating scores were measured. The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated. We searched for brain areas in which glucose metabolism correlated with the improvement of mFOG and UPDRS motor scores by DBS. During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%. There was no correlation between the improvements of both scores. The improvement of UPDRS motor score by DBS correlated with the metabolic activities of rostral supplementary motor area (Brodmann's area 8; BA8), anterior cingulate cortex (BA32), and prefrontal cortex (BA9). On the other hand, there was a positive correlation between the improvement of mFOG score by DBS and the metabolic activity of the parietal, occipital, and temporal sensory association cortices. In conclusion, dysfunction of different cerebral cortical areas limits the beneficial effects of DBS on parkinsonian motor deficits and FOG.
Lyoo
Chul Hyoung
CH
Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Aalto
Sargo
S
Rinne
Juha O
JO
Lee
Ki Ook
KO
Oh
Seung Hun
SH
Chang
Jin Woo
JW
Lee
Myung Sik
MS
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000166:cytology / Q000000981:diagnostic imaging / Q000502:physiology*; D003131:Combined Modality Therapy; D046690:Deep Brain Stimulation; D005260:Female; D019788:Fluorodeoxyglucose F18; D020233:Gait Disorders, Neurologic / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009434:Neural Pathways; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D020531:Subthalamic Nucleus / Q000166:cytology / Q000000981:diagnostic imaging / Q000502:physiology*
D000978:Antiparkinson Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D007980:Levodopa